ACCESS AND PRODUCTIVITY OUTCOMES WITH RADIOLOGY TECHNOLOGY IN WESTERN SYDNEY Outcomes despite insufficient indexation, Government funding and workforce shortages
With
Leon Berkovich, CEO
GE HealthCare Australia and New Zealand
Dr Mansoor Parker
Diagnostic & Interventional Radiologist & Founding Partner,
Quantum Radiology, Sydney
SEGMENT
Filmed in Sydney | November 2025
In Western Sydney, there is currently significant growth accompanied by a notable need for cardiovascular support due to the prevalence of related diseases. It is estimated that the population in this area will reach 6 million by 2041.
With this population growth, there is also a pressing shortage of healthcare professionals in Australia, particularly in the field of radiology, where there are not enough radiographers, sonographers, MRI technicians, and nuclear medicine technicians.
Previously, conducting complex imaging studies required the expertise of highly experienced technicians. Nonetheless, advancements in technology have enabled businesses to invest in new CT scanning technologies, from organisations such as GE HealthCare, making available the first of its kind in the Southern Hemisphere.
According to Dr. Mansoor Parker, a Diagnostic and Interventional Radiologist in Western Sydney and Founder of Quantum Radiology, the technology can produce consistent, high-quality studies that do not solely rely on the skill of the technician.
Dr. Parker spoke to Australian Health Journal about the unique nature of Western Sydney as a cultural melting pot that has historically suffered from a lack of high-quality healthcare. His motivation for establishing radiology practices in this area stemmed from his own experiences of limited access to imaging services, especially MRI and interventional procedures.
He notes that the challenges faced by the population often go beyond mere accessibility, including language barriers and the need for culturally sensitive care that respects privacy while delivering high standards of healthcare.
According to Leon Berkovich, CEO of GE HealthCare Australia & New Zealand, GE HealthCare has excelled in obtaining AI patents within the imaging sector, demonstrating significant technological adoption in Australia—a mature market where clinicians are eager to integrate the latest technology across all areas. The growth in Western Sydney continues to highlight the urgent need for cardiovascular imaging services, and demographic projections indicate robust population increases.
Source: Adapted from transcript
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
